Semantic Coherence: U.S. Food and Drug Administration โ€“ Signal Evidence & AI Readability

U.S. Food and Drug Administration

(https://www.fda.gov) ๐Ÿ“ธ Data Snapshot: May 19, 2026
Semantic Coherence โ€” The Lens

Pull the main entities out of the H1, then check whether they actually recur through the body. A page that announces one thing and then talks about another drifts. Headings with no real sentences underneath read as pseudo-substance.

Semantic Coherence Homepage promise vs. Sub-page reality.
12 Impact Weight: 20 / 100
60% Reputation

A significant semantic disconnect exists between the high-functioning, content-rich homepage and the five sub-pages analyzed, which all returned ‘Not found’ or insufficient data. While the homepage promises a comprehensive regulatory gateway with links to ‘Warning Letters’ and ‘Import Programs,’ the actual user path terminates in technical dead ends for ‘Contact FDA’ and ‘About FDA’ pages. This technical drift suggests a failure to deliver the ‘Information For’ and ‘Regulatory Information’ structures promised in the homepage H2 and H3 hierarchy. The core identity as a transparent public agency is undermined by the inability of 83% of the sampled pages to provide any substantive content.

Semantic Coherence is read from the heading hierarchy first: what each page announces in its H1 and headings, then whether the body actually delivers on it. Below is the structure the engine mapped, followed by the clean text to check for drift between promise and reality.

๐Ÿ—๏ธ Semantic Structure โ€” heading hierarchy & page identity (the promise the page makes)
HOMEPAGE U.S. Food and Drug Administration (https://www.fda.gov)
Title

U.S. Food and Drug Administration

Meta

The FDA is responsible for protecting the public health by ensuring the safety, efficacy, and security of human and veterinary drugs, biological products, and medical devices; and by ensuring the safety of our nation's food supply, cosmetics, and products that products that emit radiation

H1 FDA Releases Results from Largest-Ever Testing of Infant Formula in the U.S.
H2 Featured
H2 Products
H2 Topics
H2 Information For
H3 Featured Topics
H3 FDA in Action
H3 Press Announcements
H3 Products We Regulate
H4 FDA Finalizes Food Chemical Safety Post-Market Assessment Program, Launches Reassessment of BHT, ADA
H4 FDA Advances Drug Repurposing to Address Unmet Medical Needs
H4 FDA Grants Seventh Approval under the National Priority Voucher Pilot Program
HEADING_REPEATED_FOOTER (https://fda.gov/about-fda/about-website/language-assistance-services/)
NAV_HEADER_HEADING_REPEATED_FOOTER (https://fda.gov/about-fda/contact-fda/)
NAV_HEADER_HEADING_REPEATED_FOOTER (https://fda.gov/about-fda/)
NAV_HEADER_HEADING_REPEATED_BODY (https://fda.gov/regulatory-information/search-fda-guidance-documents/)
NAV_HEADER_HEADING_REPEATED_BODY (https://fda.gov/safety/recalls-market-withdrawals-safety-alerts/)
๐Ÿ“ The Narrative โ€” clean text per page (homepage promise vs. sub-page reality)
HOMEPAGE (https://www.fda.gov) U.S. Food and Drug Administration
Topic Paragraphs

[IMG: Woman looking at cans of infant formula in a store]

[H1] FDA Releases Results from Largest-Ever Testing of Infant Formula in the U.S.

The FDA announced results from the largest and most rigorous examination ever conducted focused on chemical contaminants in infant formula available on the U.S. market. While breast milk is widely considered the gold standard and optimal source of nutrition for infants whenever possible, millions of parents depend on formula.

[H3] Featured Topics

Recalls

Report a Problem

Warning Letters

Consumer Updates

483s

EUAs

510Ks

Guidance Documents

Drug Databases

Import Program

[H3] FDA in Action

FDA Voices: How FDA is Implementing Landmark Cosmetics Legislation to Positively Impact Public Health

FDA Achieves Year 1 Goals in Reducing Animal Testing in Drug Development

FDA Takes Action to Advance Gene Therapy Development

FDA PreCheck Pilot Program Strengthens Domestic Pharmaceutical Manufacturing

Agency Unveils Real-Time Trial Proofs-of-Concept and Upcoming Pilot Program

FDA Finalizes Food Chemical Safety Post-Market Assessment Program, Launches Reassessment of BHT, ADA

FDA Approves First-Ever Gene Therapy for Treatment of Genetic Hearing Loss

[H3] Press Announcements

May 12, 2026
[H4]
FDA Finalizes Food Chemical Safety Post-Market Assessment Program, Launches Reassessment of BHT, ADA

May 11, 2026
[H4]
FDA Advances Drug Repurposing to Address Unmet Medical Needs

May 08, 2026
[H4]
FDA Grants Seventh Approval under the National Priority Voucher Pilot Program

Newsroom

[H3] Products We Regulate

Food

Drugs

Medical Devices

Radiation-Emitting Products

Vaccines, Blood, and Biologics

Animal and Veterinary

Cosmetics

Tobacco Products
1977 chars
SUB-PAGE ยท THIN (https://fda.gov/about-fda/about-website/language-assistance-services/)
Not found
9 chars
SUB-PAGE ยท THIN (https://fda.gov/about-fda/contact-fda/)
Not found
9 chars
SUB-PAGE ยท THIN (https://fda.gov/about-fda/)
Not found
9 chars
SUB-PAGE ยท THIN (https://fda.gov/regulatory-information/search-fda-guidance-documents/)
Not found
9 chars
SUB-PAGE ยท THIN (https://fda.gov/safety/recalls-market-withdrawals-safety-alerts/)
Not found
9 chars